Company intelligence / Profile preview
Byondis
Nijmegen, Gelderland, Netherlandsbyondis.com ↗
- Ownership
- Private
- Employees
- ~350
- Development stage
- Other
01
Overview
Byondis has a wholly owned pipeline of next-generation ADCs and mAbs targeting validated cancer antigens. Lead programs are advancing through early clinical trials with a focus on improved selectivity, efficacy, and safety profiles. The company leverages proprietary linker-payload technologies to optimize therapeutic windows.
- Therapeutic areas
- OphthalmologyHematologyOncology
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)Small molecules
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Open to collaborations with research institutions and biopharmaceutical companies but no specific major partnerships disclosed as of now.
Beyond the preview
Go deeper on Byondis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Byondis.